This is a promotional press release FROM THE COMPANY THAT IS MANUFACTURING AND PROMOTING THE DRUG AND THEIR PR FIRM. I would appreciate it if in the future, anyone who wishes to have something like this put up on the OCF site send it to me, and I will see that it ends up in the NEWS section of the site where other preliminary reports on drugs in clinical trials appear. It contains PRELIMINARY DATA AND FINDINGS, not conclusive results. It also contains information that is not based on sound fact (death rates of those in recurrence, which I have gone in and edited out of the original posting) designed to influence potential investors in this firm. Given that Dan, do not read too much into what this says about the death rate. I will take down posts like this one in the future. While they contain some useful information, (to investors, not us

Brian, stage 4 oral cancer survivor. OCF Founder and Director. The first responsibility of a leader is to define reality. The last is to say thank you. In between, the leader is a servant.